Major grocery store chain issues urgent recall on products over contamination — here's what you need to know
German-owned discount retailer Lidl has issued an urgent recall to its UK stores due to concerns that some of its products have been contaminated by plastic.
Lidl is one of the most popular supermarket chains in the UK, with 980 branches in operation since it first opened in 1994. The recall was issued on May 15 by the UK Food Standards Agency and concerns packs of snack bars made by Alesto.
The warning covers four products: cocoa & orange, blueberry muffin, salted caramel, and berry raw fruit and nut bars with the best before date of November to December 2025.
The risk statement informed about "the possible presence of pieces of plastic in the products which makes them unsafe to eat." The company has urged customers who may have purchased the snacks to return them to the store for a full refund.
Recalls for unsafe food products happen quite regularly, and plastic contamination is becoming an increasingly common cause. While it might be a practical and cheap material for packaging, it comes with risks to consumer health and the environment. As it breaks down, it releases microplastics, which have been found in every corner of the planet.
Although the actual long-term effects of microplastic contamination are still not fully understood, experts have linked it to a range of health issues. These include respiratory problems, digestive issues, reproductive concerns, and cardiovascular risks.
It's not just packaging that can lead to microplastic contamination. Because plastics are so ubiquitous, production has doubled in the last decade, according to Our World in Data. They get into the food supply through the soil that grows vegetables and the oceans that produce seafood.
Food recalls help maintain safety, but this instance, and many others like it, highlight the urgency of reducing plastic use. Further research into the long-term effects of microplastics and coordinated action against their use are also needed.
Additionally, plastic containers should not be used for food, and consumers should try to make wise, sustainable shopping choices at the supermarket.
Should grocery stores donate food that's past its sell-by date?
Yes — as long as it's not bad
Yes — but only certain foods
Only if it doesn't cost the store
No — it could lead to problems
Click your choice to see results and speak your mind.
Join our free newsletter for easy tips to save more and waste less, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Tagomics awarded £860k grant for colorectal cancer diagnostic
Tagomics has been awarded £860,000 ($1.1m) from Innovate UK to develop a test for diagnosing early-stage colorectal cancer (CRC). The Cambridge, UK-based company said the money from the UK government innovation agency's Biomedical Catalyst programme would help fund a £1.2m project that is applying its Interlace multiomics workflow platform towards the detection of genetic and epigenetic mutations associated with CRC. This includes the development of new models for analysing patients' multiomic profiles to identify new disease biomarkers. Once the project concludes, a pilot study of the diagnostic test will be undertaken with the UK National Health Service (NHS). Led by Dr Arash Assadsangabi, consultant physician and gastroenterologist at Salford Royal NHS Foundation Trust, in collaboration with the Northern Care Alliance Research Collection biobank, the study will profile 250 patients suspected of having CRC to validate identified biomarkers and demonstrate multiomic profiling's efficacy in the early detection of the disease. Tagomics' chief scientific officer and co-founder, Dr Robert Neely said: 'We believe that the unique, information-rich dataset that Interlace provides us will be pivotal in detecting CRC at the earliest possible stages of development, enabling treatment of the cancer when it is most vulnerable to modern therapeutics, with the aim of dramatically improving patient outcomes.' Upon completion of the project, Tagomics will look to further expand the capabilities and applications of its Interlace platform with the support of Agilent Technologies, building on an established partnership that was key to the early development of the platform, Dr Neely added. The American Cancer Society estimates that there will be 107,320 new cases of colon cancer and 46,950 new cases of rectal cancer in 2025. According to GlobalData analysis, with early detection of CRC critical in reducing the disease's mortality rate, in vitro diagnostic (IVD) tests have a critical role to play in bridging the disease's screening gap, with company's such as Guardant Health at work on developing patient-first tests to create solutions that make patient care more accessible. Guardant's SHIELD test, which was approved by the US Food and Drug Administration (FDA) as a primary screening option for CRC in 2024, is intended to detect alterations in the blood associated with CRC. "Tagomics awarded £860k grant for colorectal cancer diagnostic" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
2 hours ago
- Medscape
Mavacamten Showing Real-World Success in Treating oHCM
MANCHESTER — Mavacamten (Camzyos, Bristol Myers Squibb) continues to show promising results in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a consultant cardiologist said at the recent British Cardiovascular Society Annual Conference 2025. William Jenkins, a consultant cardiologist at the Royal Infirmary of Edinburgh, said that real world outcomes mirror those from clinical trials, including EXPLORER and VALOR-HCM. High Rates of Symptom Improvement Notably, data from three UK centres showed that about 70%-80% of patients experienced symptomatic improvement with mavacamten treatment. In addition, 90% saw a 30mmHg drop in the left ventricular outflow tract (LVOT) gradient – considered a significant reduction in obstruction. William Jenkins Although patients initially required 'very intense echocardiographic surveillance', Jenkins said 'it gets much easier' after the first few months of treatment. 'I think our reliance upon echocardiography will probably reduce as we get more experience with this,' he told Medscape News UK . A First-in-Class Therapy Mavacamten, a cardiac myosin inhibitor, is the first drug of its kind. It works by normalising contractility, reducing dynamic LVOT obstruction, and improving cardiac filling pressures in people with HCM. 'HCM is something that develops over decades,' Jenkins said. 'You can develop symptoms early, but you can have those symptoms for a really long time before you go on to develop other things like abnormal heart rhythms, heart failure, or dying suddenly.' He added that although oHCM is considered rare, many patients could benefit from treatment. Managing HCM still falls within general cardiology in some centres, Jenkins noted, raising concerns that patients may not be reviewed as frequently as needed. 'People live with it for years and years — if not decades — before they develop any of the end stage features of HCM,' Jenkins said. 'They can become very adapted to their symptoms.' Patient Advocacy and Experience Hypertrophic cardiomyopathy affects around 1 in 500 people in the UK and US, with about two thirds of cases involving obstruction. Katharine McIntosh, head of research and policy at Cardiomyopathy UK, told Medscape News UK that mavacamten had been a 'cause for excitement' among patients. 'It's the first big cardiomyopathy-specific drug.' McIntosh expressed frustration at the slow rollout of the drug, which was recommended for NHS use in England and Wales in 2023 and in Scotland in 2024. 'It's at the point now where one would have thought that everyone who should be on it would be getting onto it. But that's just not been the case,' she said. A recent Cardiomyopathy UK survey found that patients who accessed mavacamten were 'very positive' about its effects. Respondents described it as 'life changing' and felt like they had been given their lives back, McIntosh said. Challenges Facing Widespread Use One barrier is that mavacamten must be prescribed and monitored by specialists experienced in treating cardiomyopathies – resources not available at all centres. Prescribing guidance states that patients require echocardiography before and at regular intervals after starting treatment. Genetic testing for Cytochrome P450 (CYP) 2C19 (CYP2C19) is also needed to guide dosing. Long-Term Outlook Jenkins said that three key issues must be considered before prescribing mavacamten: Close early monitoring is needed, as the drug can cause left ventricular systolic dysfunction. CYP2C19-related drug interactions require pharmacy input. Counselling is essential due to potential foetal toxicity risks. 'Most people tolerate this [drug] very well', he said. After the initial 12-week period, follow-up can be reduced to every 3-6 months. 'This is an indefinite medication for a lot of people' Jenkins said. However, with an estimated annual cost of almost £14,000 per patient, he stressed the need for careful initial use. 'Right now, the indication is for symptomatic, severe LVOT obstruction,' he said. However, 'there's no reason in the long-term why this shouldn't become first-line'. Whether mavacamten offers benefit for oHCM patients without obstruction remains unclear. Jenkins has acted as a consultant to BMS and AstraZeneca. McIntosh had no conflicts of interest to disclose.
Yahoo
5 hours ago
- Yahoo
‘Boil in the bag' funerals could be introduced in UK after European roll-out in Ireland
"Boil in a bag" funerals - already used widely in America - could soon be made available across the UK. This environmentally friendly, yet controversial, way to say your final goodbyes to a loved one has already been rolled out in Ireland back in 2023 and could come to the UK next. This unusual method, officially known as water cremation or alkaline hydrolysis, is currently effectively banned in the UK, but could well get the legal go-ahead following the independent Law Commission's new consultation into funerary methods. READ MORE: Dad, 32, who flew to Turkey for family holiday dies hours after being escorted off plane READ MORE: Met Office verdict on UK heatwave this WEEK as temperatures to climb to 29C Already available across 30 US states, as well as Canada and South Africa, the first European water cremation facility, or resomation, opened its doors in early 2023 in Navan, Co Meath, Ireland. Traditional burials can lead to embalming fluid seeping into the grave soil, while each gas-powered fire cremation releases around 245kg of CO2 into the atmosphere, according to UK-based cemetery and crematorium development the CDS Group. By comparison, figures from Resomation Ltd, the founding body for alkaline hydrolysis, show just 28kg of CO2 is released into the atmosphere per water cremation. Unlike conventional cremations, these eco-friendly farewells, which take between three to four hours, also don't release harmful mercury emissions into the atmosphere. But you might be wondering how the process actually works. Well, first the body is loaded into the alkaline hydrolysis machine, which calculates the amount of water and potassium hydroxide required. The machine locks and an alkaline solution fills the pressurised tank, which is gently heated to 152C. The remains get broken into their chemical components - amino acids, peptides, sugars and salt - leaving behind a liquid that is then cooled in another tank until sterile and free from any remaining tissue or DNA. Around 330 gallons of brown-coloured liquid will be washed down the drain, while the softened bones are ground to powder in a reducer, and presented in an urn to the grieving family. In 2017, Wired journalist Hayley Campbell described the process in colourful detail after seeing a resomator in action at the University of California, Los Angeles (UCLA). Hayley wrote: "Over the course of up to four hours, the strong alkaline base causes everything but the skeleton to break down to the original components that built it: sugar, salt, peptides and amino acids; DNA unzips into its nucleobases, cytosine, guanine, adenine, thymine. "The body becomes fertiliser and soap, a sterile watery liquid that looks like weak tea. The liquid shoots through a pipe into a holding tank in the opposite corner of the room, where it will cool down, be brought down to an acceptable pH for the water treatment plant, and be released down the drain." Noting that "it's not actually that terrible", Hayley revealed: "The human body, liquefied, smells like steamed clams." Highlighting why this process is still a bit of a taboo in an interview with The Telegraph, Dr Lian Lundy, a wastewater specialist from Middlesex University, explained: "Some people view it as basically mixing up my loved one with poo in the sewer and they don't like that. "But there's a lot that goes into the sewer that we don't really think about – waste from mortuaries and hospitals and all sorts of things that we don't know about – so from that perspective, it's not really any different."
